Core Viewpoint - The company has experienced rapid growth in its CDMO projects, which are now entering the commercialization phase, contributing to an increase in CDMO capacity utilization [2] Group 1: CDMO Project Growth - The number of CDMO projects has been steadily increasing in recent years [2] - The transition to commercial production is expected to enhance capacity utilization for CDMO [2] Group 2: Business Performance Insights - The CDMO projects and capacity involve multiple subsidiaries and numerous production lines, indicating that strong performance in some production lines does not fully represent the overall business situation [2] - The company advises investors to rely on disclosed announcements for accurate business performance assessments and to exercise caution in their analyses [2]

Core Viewpoint - The company has reported a significant increase in CDMO orders for Q1 2026, with a year-on-year growth of 100%, indicating strong confidence in achieving record profits in 2026 [1] Group 1: CDMO Project Growth - The company has experienced rapid growth in its CDMO projects in recent years, which are gradually entering the commercial production phase [1] - Increased utilization of CDMO capacity is expected as a result of this growth [1] Group 2: Production Capacity and Business Outlook - The CDMO projects and production capacity involve multiple subsidiaries and numerous production lines, meaning that strong performance in some production lines does not fully represent the overall business situation [1] - The company advises investors to rely on disclosed announcements for accurate performance expectations and to exercise caution in their analyses [1]

Core Viewpoint - Pro Pharmaceutical (000739) has signed a strategic cooperation framework agreement with Hangzhou Derui Zhiyao Technology Co., Ltd. to engage in long-term collaboration on CDMO projects, enhancing its competitive edge in the CDMO business [1]. Group 1 - The strategic cooperation agreement establishes a partnership based on mutual benefits and complementary advantages between Pro Pharmaceutical and Derui Zhiyao [1]. - The collaboration aims to promote the application of relevant technologies in Pro Pharmaceutical's CDMO projects, from process development to large-scale production [1]. - This partnership is expected to facilitate the expansion of Pro Pharmaceutical's CDMO business, thereby improving its competitiveness in the industry [1].

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Hangzhou Derui Zhiyao Technology Co., Ltd. to establish a long-term partnership for CDMO projects, emphasizing mutual benefits and complementary advantages [1] Group 1 - The agreement is a framework agreement and does not involve substantial transactions [1] - The agreement does not constitute a related party transaction [1] - The agreement does not fall under the major asset restructuring regulations as per the listed company management measures [1] Group 2 - The signing of the strategic framework agreement does not require approval from the company's board of directors or shareholders [1]

Core Viewpoint - Pro Pharmaceutical (000739) has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO) [1] Group 1: Strategic Cooperation - The agreement establishes a strategic partnership between Pro Pharmaceutical and Xi'an New Tong, focusing on long-term collaboration in CDMO projects [1] - This collaboration is expected to enhance Pro Pharmaceutical's CDMO business competitiveness and facilitate its expansion in this sector [1] Group 2: Xi'an New Tong's IPO - Xi'an New Tong is currently preparing for an IPO on the Sci-Tech Innovation Board, with its application accepted on December 29, 2025, aiming to raise 900 million yuan [1]

Core Viewpoint - The company, Pro Pharmaceutical (000739), has signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO projects) [1] Group 1 - The collaboration aims to expand the company's CDMO business and enhance its competitiveness in the CDMO sector [1]